User:Tkadm30/Notebook/Aripiprazole: Difference between revisions
From OpenWetWare
< User:Tkadm30 | Notebook
No edit summary |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 5: | Line 5: | ||
* [https://www.ncbi.nlm.nih.gov/pubmed/24045880 Repeated aripiprazole treatment causes dopamine D2 receptor up-regulation and dopamine supersensitivity in young rats.] | * [https://www.ncbi.nlm.nih.gov/pubmed/24045880 Repeated aripiprazole treatment causes dopamine D2 receptor up-regulation and dopamine supersensitivity in young rats.] | ||
* [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498891/ Unique Effects of Acute Aripiprazole Treatment on the Dopamine D2 Receptor Downstream cAMP-PKA and Akt-GSK3β Signalling Pathways in Rats] | * [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498891/ Unique Effects of Acute Aripiprazole Treatment on the Dopamine D2 Receptor Downstream cAMP-PKA and Akt-GSK3β Signalling Pathways in Rats] | ||
* [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951756/ Chronic administration of aripiprazole activates GSK3β-dependent signalling pathways, and up-regulates GABAA receptor expression and CREB1 activity in rats] | |||
===Corticostriatal glutamatergic transmission=== | ===Corticostriatal glutamatergic transmission=== | ||
* [http://www.thenakedscientists.com/forum/index.php?topic=69151.0 Heteromeric adenosine-CB1 activation increase functional connectivity at dopamine D2 receptors?] | * [http://www.thenakedscientists.com/forum/index.php?topic=69151.0 Heteromeric adenosine-CB1 activation increase functional connectivity at dopamine D2 receptors?] | ||
* [http://www.komci.org/GSResult.php?RID=0195CPN%2F2011.9.1.36&DT=6 Effects of Aripiprazole and Haloperidol on Fos-like Immunoreactivity in the Prefrontal Cortex] | * [http://www.komci.org/GSResult.php?RID=0195CPN%2F2011.9.1.36&DT=6 Effects of Aripiprazole and Haloperidol on Fos-like Immunoreactivity in the Prefrontal Cortex] | ||
===Side effects=== | ===Side effects=== | ||
* [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666545/ Worsened hypertension control induced by aripiprazole] | * [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666545/ Worsened hypertension control induced by aripiprazole] | ||
===See also=== | ===See also=== | ||
* [https://en.wikipedia.org/wiki/Aripiprazole Aripiprazole] | * [https://en.wikipedia.org/wiki/Aripiprazole Aripiprazole] | ||
Revision as of 13:04, 21 March 2017
Functional selectivity of aripiprazole at D2 receptors
- Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways.
- Protective effect of aripiprazole against glutamate cytotoxicity in dopaminergic neurons of rat mesencephalic cultures.
- Antagonism of the adenosine A2A receptor attenuates akathisia-like behavior induced with MP-10 or aripiprazole in a novel non-human primate model.
- Repeated aripiprazole treatment causes dopamine D2 receptor up-regulation and dopamine supersensitivity in young rats.
- Unique Effects of Acute Aripiprazole Treatment on the Dopamine D2 Receptor Downstream cAMP-PKA and Akt-GSK3β Signalling Pathways in Rats
- Chronic administration of aripiprazole activates GSK3β-dependent signalling pathways, and up-regulates GABAA receptor expression and CREB1 activity in rats
Corticostriatal glutamatergic transmission
- Heteromeric adenosine-CB1 activation increase functional connectivity at dopamine D2 receptors?
- Effects of Aripiprazole and Haloperidol on Fos-like Immunoreactivity in the Prefrontal Cortex
